ECTS Abstracts (2015) 1 P427

Aromatase Inhibitors in Breast Cancer and Bone Status

Kawtar nassar, Wafae Rachidi, Saadia Janani & Ouafa Mkinsi


Rheumatology department, Ibn Rochd University Hospital, Casablanca, Morocco.


Background: The hormonomodulator character of breast cancer justifies the use of treatments that are the cause of hypogonadism, bone loss and an increased risk fracture. The objective of the study: Evaluation of bone status in patients followed for breast cancer, under anti-aromatase, admitted in rheumatology for bone status evaluation.

Methods: Prospective study, preliminary, conducted in 51 patients followed for breast cancer and views in rheumatology for evaluation of bone status. Inclusion criteria were patients followed for infiltrating ductal carcinoma, taking aromatase inhibitor, naive of anti-osteoporotic treatment. Exclusion criteria were patients taking osteoporosis treatment, those with other risk factors for bone fragility and those with a history of fracture. All patients had a complete physical examination. A calcium and phosphate levels, the dosage of vitamin D and parathyroid hormone was performed in our patients.

Results: Among patients, 38 met the inclusion criteria. The mean age was 59+/- 10 years. All received radiation therapy and chemotherapy after mastectomy. All were postmenopausal. Breast cancer was unilateral in 36 cases. The average duration of taking hormone therapy was 3 years +/- 2. Mean serum calcium was 95 g / l, mean serum phosphorus at 34 g/l, the average value of vitamin D was 25 ng / ml. The average parathyroid hormone at 69.86 pg/l. 29 patients had a T-score <or equal to -2 to at least one site from the spine and hip. In contrast, 9 cases had a T-score> - 2 to 3 sites. Among the patients with T-score <-2, 16 cases had normal vitamin D status, and 13 were inadequate. These have benefited from vitamin D supplementation and then oral bisphosphonates.

Conclusion: Our results are conforming with those found in the literature. Treatments hormonomodulators of breast cancers cause bone loss and fracture risk, justifying osteoporotic patients before starting treatment. Bisphosphonate therapy is indicated for fractures and / or densitometric osteoporosis.

Disclosure: The authors declared no competing interests.

Article tools

My recent searches

No recent searches.

My recently viewed abstracts